SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - NuVasive, Inc. (
- The Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, November 27, 2012, at 10:00 a.m. EST.
- The RBC Capital Markets Healthcare Investor Day at the JW Marriot in Denver, Colorado, on Thursday, November 29, 2012.
- Jefferies' San Diego MedTech Bus Tour at NuVasive's headquarters in San Diego, CA, on Monday, December 3, 2012, at 11:00 a.m. PT.
- Leerink Swan's Devices and DNA Bus Tour at NuVasive's headquarters in San Diego, CA, on Tuesday, December 11, 2012, at 10:00 a.m. PT.
A live webcast of the Piper Jaffray presentation and of each of the Bus Tours will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcasts, a replay of the presentations will remain available on the website for 30 days.
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $7.9 billion global spine market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 75 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may refuse to reimburse healthcare providers for the use of NuVasive's products the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.